Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,431
archived clinical trials in
Anemia

An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A
A Phase I/III Open-label, Multicenter, Crossover Safety, Efficacy and Pharmacokinetic Study of Recombinant Coagulation Factor VIII (rFVIII) Compared to Recombinant Human Antihaemophilic Factor VIII (rFVIII; INN: Octocog Alfa) in Subjects With Hemophilia A, and a Repeat PK, Safety and Efficacy Study
Status: Enrolling
Updated:  12/11/2015
Clinical Research Facility
mi
from
Aurora, CO
An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A
A Phase I/III Open-label, Multicenter, Crossover Safety, Efficacy and Pharmacokinetic Study of Recombinant Coagulation Factor VIII (rFVIII) Compared to Recombinant Human Antihaemophilic Factor VIII (rFVIII; INN: Octocog Alfa) in Subjects With Hemophilia A, and a Repeat PK, Safety and Efficacy Study
Status: Enrolling
Updated: 12/11/2015
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A
A Phase I/III Open-label, Multicenter, Crossover Safety, Efficacy and Pharmacokinetic Study of Recombinant Coagulation Factor VIII (rFVIII) Compared to Recombinant Human Antihaemophilic Factor VIII (rFVIII; INN: Octocog Alfa) in Subjects With Hemophilia A, and a Repeat PK, Safety and Efficacy Study
Status: Enrolling
Updated:  12/11/2015
Clinical Research Facility
mi
from
Hartford, CT
An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A
A Phase I/III Open-label, Multicenter, Crossover Safety, Efficacy and Pharmacokinetic Study of Recombinant Coagulation Factor VIII (rFVIII) Compared to Recombinant Human Antihaemophilic Factor VIII (rFVIII; INN: Octocog Alfa) in Subjects With Hemophilia A, and a Repeat PK, Safety and Efficacy Study
Status: Enrolling
Updated: 12/11/2015
Clinical Research Facility
mi
from
Hartford, CT
Click here to add this to my saved trials
An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A
A Phase I/III Open-label, Multicenter, Crossover Safety, Efficacy and Pharmacokinetic Study of Recombinant Coagulation Factor VIII (rFVIII) Compared to Recombinant Human Antihaemophilic Factor VIII (rFVIII; INN: Octocog Alfa) in Subjects With Hemophilia A, and a Repeat PK, Safety and Efficacy Study
Status: Enrolling
Updated:  12/11/2015
Clinical Research Facility
mi
from
Miami, FL
An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A
A Phase I/III Open-label, Multicenter, Crossover Safety, Efficacy and Pharmacokinetic Study of Recombinant Coagulation Factor VIII (rFVIII) Compared to Recombinant Human Antihaemophilic Factor VIII (rFVIII; INN: Octocog Alfa) in Subjects With Hemophilia A, and a Repeat PK, Safety and Efficacy Study
Status: Enrolling
Updated: 12/11/2015
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A
A Phase I/III Open-label, Multicenter, Crossover Safety, Efficacy and Pharmacokinetic Study of Recombinant Coagulation Factor VIII (rFVIII) Compared to Recombinant Human Antihaemophilic Factor VIII (rFVIII; INN: Octocog Alfa) in Subjects With Hemophilia A, and a Repeat PK, Safety and Efficacy Study
Status: Enrolling
Updated:  12/11/2015
Clinical Research Facility
mi
from
Chicago, IL
An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A
A Phase I/III Open-label, Multicenter, Crossover Safety, Efficacy and Pharmacokinetic Study of Recombinant Coagulation Factor VIII (rFVIII) Compared to Recombinant Human Antihaemophilic Factor VIII (rFVIII; INN: Octocog Alfa) in Subjects With Hemophilia A, and a Repeat PK, Safety and Efficacy Study
Status: Enrolling
Updated: 12/11/2015
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A
A Phase I/III Open-label, Multicenter, Crossover Safety, Efficacy and Pharmacokinetic Study of Recombinant Coagulation Factor VIII (rFVIII) Compared to Recombinant Human Antihaemophilic Factor VIII (rFVIII; INN: Octocog Alfa) in Subjects With Hemophilia A, and a Repeat PK, Safety and Efficacy Study
Status: Enrolling
Updated:  12/11/2015
Clinical Research Facility
mi
from
New Orleans, LA
An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A
A Phase I/III Open-label, Multicenter, Crossover Safety, Efficacy and Pharmacokinetic Study of Recombinant Coagulation Factor VIII (rFVIII) Compared to Recombinant Human Antihaemophilic Factor VIII (rFVIII; INN: Octocog Alfa) in Subjects With Hemophilia A, and a Repeat PK, Safety and Efficacy Study
Status: Enrolling
Updated: 12/11/2015
Clinical Research Facility
mi
from
New Orleans, LA
Click here to add this to my saved trials
An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A
A Phase I/III Open-label, Multicenter, Crossover Safety, Efficacy and Pharmacokinetic Study of Recombinant Coagulation Factor VIII (rFVIII) Compared to Recombinant Human Antihaemophilic Factor VIII (rFVIII; INN: Octocog Alfa) in Subjects With Hemophilia A, and a Repeat PK, Safety and Efficacy Study
Status: Enrolling
Updated:  12/11/2015
Clinical Research Facility
mi
from
Las Vegas, NV
An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A
A Phase I/III Open-label, Multicenter, Crossover Safety, Efficacy and Pharmacokinetic Study of Recombinant Coagulation Factor VIII (rFVIII) Compared to Recombinant Human Antihaemophilic Factor VIII (rFVIII; INN: Octocog Alfa) in Subjects With Hemophilia A, and a Repeat PK, Safety and Efficacy Study
Status: Enrolling
Updated: 12/11/2015
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A
A Phase I/III Open-label, Multicenter, Crossover Safety, Efficacy and Pharmacokinetic Study of Recombinant Coagulation Factor VIII (rFVIII) Compared to Recombinant Human Antihaemophilic Factor VIII (rFVIII; INN: Octocog Alfa) in Subjects With Hemophilia A, and a Repeat PK, Safety and Efficacy Study
Status: Enrolling
Updated:  12/11/2015
Clinical Research Facility
mi
from
Dallas, TX
An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A
A Phase I/III Open-label, Multicenter, Crossover Safety, Efficacy and Pharmacokinetic Study of Recombinant Coagulation Factor VIII (rFVIII) Compared to Recombinant Human Antihaemophilic Factor VIII (rFVIII; INN: Octocog Alfa) in Subjects With Hemophilia A, and a Repeat PK, Safety and Efficacy Study
Status: Enrolling
Updated: 12/11/2015
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A
A Phase I/III Open-label, Multicenter, Crossover Safety, Efficacy and Pharmacokinetic Study of Recombinant Coagulation Factor VIII (rFVIII) Compared to Recombinant Human Antihaemophilic Factor VIII (rFVIII; INN: Octocog Alfa) in Subjects With Hemophilia A, and a Repeat PK, Safety and Efficacy Study
Status: Enrolling
Updated:  12/11/2015
Clinical Research Facility
mi
from
Houston, TX
An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A
A Phase I/III Open-label, Multicenter, Crossover Safety, Efficacy and Pharmacokinetic Study of Recombinant Coagulation Factor VIII (rFVIII) Compared to Recombinant Human Antihaemophilic Factor VIII (rFVIII; INN: Octocog Alfa) in Subjects With Hemophilia A, and a Repeat PK, Safety and Efficacy Study
Status: Enrolling
Updated: 12/11/2015
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A
A Phase I/III Open-label, Multicenter, Crossover Safety, Efficacy and Pharmacokinetic Study of Recombinant Coagulation Factor VIII (rFVIII) Compared to Recombinant Human Antihaemophilic Factor VIII (rFVIII; INN: Octocog Alfa) in Subjects With Hemophilia A, and a Repeat PK, Safety and Efficacy Study
Status: Enrolling
Updated:  12/11/2015
Clinical Research Facility
mi
from
Milwaukee, WI
An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A
A Phase I/III Open-label, Multicenter, Crossover Safety, Efficacy and Pharmacokinetic Study of Recombinant Coagulation Factor VIII (rFVIII) Compared to Recombinant Human Antihaemophilic Factor VIII (rFVIII; INN: Octocog Alfa) in Subjects With Hemophilia A, and a Repeat PK, Safety and Efficacy Study
Status: Enrolling
Updated: 12/11/2015
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A
A Phase I/III Open-label, Multicenter, Crossover Safety, Efficacy and Pharmacokinetic Study of Recombinant Coagulation Factor VIII (rFVIII) Compared to Recombinant Human Antihaemophilic Factor VIII (rFVIII; INN: Octocog Alfa) in Subjects With Hemophilia A, and a Repeat PK, Safety and Efficacy Study
Status: Enrolling
Updated:  12/11/2015
Clinical Research Facility
mi
from
San Diego, CA
An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A
A Phase I/III Open-label, Multicenter, Crossover Safety, Efficacy and Pharmacokinetic Study of Recombinant Coagulation Factor VIII (rFVIII) Compared to Recombinant Human Antihaemophilic Factor VIII (rFVIII; INN: Octocog Alfa) in Subjects With Hemophilia A, and a Repeat PK, Safety and Efficacy Study
Status: Enrolling
Updated: 12/11/2015
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A
A Phase I/III Open-label, Multicenter, Crossover Safety, Efficacy and Pharmacokinetic Study of Recombinant Coagulation Factor VIII (rFVIII) Compared to Recombinant Human Antihaemophilic Factor VIII (rFVIII; INN: Octocog Alfa) in Subjects With Hemophilia A, and a Repeat PK, Safety and Efficacy Study
Status: Enrolling
Updated:  12/11/2015
mi
from
Nedlands,
An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A
A Phase I/III Open-label, Multicenter, Crossover Safety, Efficacy and Pharmacokinetic Study of Recombinant Coagulation Factor VIII (rFVIII) Compared to Recombinant Human Antihaemophilic Factor VIII (rFVIII; INN: Octocog Alfa) in Subjects With Hemophilia A, and a Repeat PK, Safety and Efficacy Study
Status: Enrolling
Updated: 12/11/2015
mi
from
Nedlands,
Click here to add this to my saved trials
Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis
Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis: A Randomized, Double Blind Placebo Controlled Trial
Status: Enrolling
Updated:  12/18/2015
Children's Hospital at Montefiore
mi
from
Bronx, NY
Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis
Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis: A Randomized, Double Blind Placebo Controlled Trial
Status: Enrolling
Updated: 12/18/2015
Children's Hospital at Montefiore
mi
from
Bronx, NY
Click here to add this to my saved trials
Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
Status: Enrolling
Updated:  12/21/2015
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
Status: Enrolling
Updated: 12/21/2015
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
Status: Enrolling
Updated:  12/21/2015
Baylor College of Medicine
mi
from
Houston, TX
Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
Status: Enrolling
Updated: 12/21/2015
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
Status: Enrolling
Updated:  12/21/2015
Children's Hospital of Michigan
mi
from
Detroit, MI
Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
Status: Enrolling
Updated: 12/21/2015
Children's Hospital of Michigan
mi
from
Detroit, MI
Click here to add this to my saved trials
Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
Status: Enrolling
Updated:  12/21/2015
Children's Hospital of Philadelphia Research Institute
mi
from
Philadelphia, PA
Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
Status: Enrolling
Updated: 12/21/2015
Children's Hospital of Philadelphia Research Institute
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
Status: Enrolling
Updated:  12/21/2015
Medical College of Wisconsin
mi
from
Milwaukee, WI
Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
Status: Enrolling
Updated: 12/21/2015
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
Status: Enrolling
Updated:  12/21/2015
University of Pittsburgh
mi
from
Pittsburgh, PA
Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
Status: Enrolling
Updated: 12/21/2015
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
Status: Enrolling
Updated:  12/21/2015
Johns Hopkins Hospital
mi
from
Baltimore, MD
Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
Status: Enrolling
Updated: 12/21/2015
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
Status: Enrolling
Updated:  12/21/2015
Nationwide Children's Hospital
mi
from
Columbus, OH
Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
Status: Enrolling
Updated: 12/21/2015
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Status: Enrolling
Updated:  12/21/2015
Children's Hospital of Orange County Onc Dept
mi
from
Orange, CA
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Status: Enrolling
Updated: 12/21/2015
Children's Hospital of Orange County Onc Dept
mi
from
Orange, CA
Click here to add this to my saved trials
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Status: Enrolling
Updated:  12/21/2015
Children's Hospital of Orange County Onc Dept
mi
from
Orange, CA
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Status: Enrolling
Updated: 12/21/2015
Children's Hospital of Orange County Onc Dept
mi
from
Orange, CA
Click here to add this to my saved trials
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Status: Enrolling
Updated:  12/21/2015
Lurie Children's Hospital of Chicago Onc Dept
mi
from
Chicago, IL
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Status: Enrolling
Updated: 12/21/2015
Lurie Children's Hospital of Chicago Onc Dept
mi
from
Chicago, IL
Click here to add this to my saved trials
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Status: Enrolling
Updated:  12/21/2015
Lurie Children's Hospital of Chicago Onc Dept
mi
from
Chicago, IL
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Status: Enrolling
Updated: 12/21/2015
Lurie Children's Hospital of Chicago Onc Dept
mi
from
Chicago, IL
Click here to add this to my saved trials
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Status: Enrolling
Updated:  12/21/2015
Children's Hospital Boston Department of Hematology
mi
from
Boston, MA
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Status: Enrolling
Updated: 12/21/2015
Children's Hospital Boston Department of Hematology
mi
from
Boston, MA
Click here to add this to my saved trials
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Status: Enrolling
Updated:  12/21/2015
Weill Cornell Medical College-Cornell University Onc Dept
mi
from
New York, NY
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Status: Enrolling
Updated: 12/21/2015
Weill Cornell Medical College-Cornell University Onc Dept
mi
from
New York, NY
Click here to add this to my saved trials
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Status: Enrolling
Updated:  12/21/2015
Weill Cornell Medical College-Cornell University Onc Dept
mi
from
New York, NY
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Status: Enrolling
Updated: 12/21/2015
Weill Cornell Medical College-Cornell University Onc Dept
mi
from
New York, NY
Click here to add this to my saved trials
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Status: Enrolling
Updated:  12/21/2015
Children's Hospital of Philadelphia Onc. Dept
mi
from
Philadelphia, PA
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Status: Enrolling
Updated: 12/21/2015
Children's Hospital of Philadelphia Onc. Dept
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Status: Enrolling
Updated:  12/21/2015
Children's Hospital of Philadelphia Onc. Dept
mi
from
Philadelphia, PA
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Status: Enrolling
Updated: 12/21/2015
Children's Hospital of Philadelphia Onc. Dept
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Status: Enrolling
Updated:  12/21/2015
Novartis Investigative Site
mi
from
Buenos Aires,
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Status: Enrolling
Updated: 12/21/2015
Novartis Investigative Site
mi
from
Buenos Aires,
Click here to add this to my saved trials
Strategies to Reduce Iron Deficiency
Caring for Those Who Share: Mitigating Iron Deficiency In Regular Blood Donors
Status: Enrolling
Updated:  12/21/2015
American Red Cross, Connecticut Region
mi
from
Farmington, CT
Strategies to Reduce Iron Deficiency
Caring for Those Who Share: Mitigating Iron Deficiency In Regular Blood Donors
Status: Enrolling
Updated: 12/21/2015
American Red Cross, Connecticut Region
mi
from
Farmington, CT
Click here to add this to my saved trials
Strategies to Reduce Iron Deficiency
Caring for Those Who Share: Mitigating Iron Deficiency In Regular Blood Donors
Status: Enrolling
Updated:  12/21/2015
Westat, Inc.
mi
from
Rockville, MD
Strategies to Reduce Iron Deficiency
Caring for Those Who Share: Mitigating Iron Deficiency In Regular Blood Donors
Status: Enrolling
Updated: 12/21/2015
Westat, Inc.
mi
from
Rockville, MD
Click here to add this to my saved trials
Strategies to Reduce Iron Deficiency
Caring for Those Who Share: Mitigating Iron Deficiency In Regular Blood Donors
Status: Enrolling
Updated:  12/21/2015
The Institute for Transfusion Medicince
mi
from
Pittsburgh, PA
Strategies to Reduce Iron Deficiency
Caring for Those Who Share: Mitigating Iron Deficiency In Regular Blood Donors
Status: Enrolling
Updated: 12/21/2015
The Institute for Transfusion Medicince
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Strategies to Reduce Iron Deficiency
Caring for Those Who Share: Mitigating Iron Deficiency In Regular Blood Donors
Status: Enrolling
Updated:  12/21/2015
BloodCenter of Wisconsin
mi
from
Milwaukee, WI
Strategies to Reduce Iron Deficiency
Caring for Those Who Share: Mitigating Iron Deficiency In Regular Blood Donors
Status: Enrolling
Updated: 12/21/2015
BloodCenter of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
A 5 Year Observational Study (Registry) of Children Aged 2 to <6 Years at Enrollment With Transfusional Hemosiderosis Treated With Deferasirox
Status: Enrolling
Updated:  12/26/2015
University of South Alabama Medical Center
mi
from
Mobile, AL
ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
A 5 Year Observational Study (Registry) of Children Aged 2 to <6 Years at Enrollment With Transfusional Hemosiderosis Treated With Deferasirox
Status: Enrolling
Updated: 12/26/2015
University of South Alabama Medical Center
mi
from
Mobile, AL
Click here to add this to my saved trials
ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
A 5 Year Observational Study (Registry) of Children Aged 2 to <6 Years at Enrollment With Transfusional Hemosiderosis Treated With Deferasirox
Status: Enrolling
Updated:  12/26/2015
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
A 5 Year Observational Study (Registry) of Children Aged 2 to <6 Years at Enrollment With Transfusional Hemosiderosis Treated With Deferasirox
Status: Enrolling
Updated: 12/26/2015
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
A 5 Year Observational Study (Registry) of Children Aged 2 to <6 Years at Enrollment With Transfusional Hemosiderosis Treated With Deferasirox
Status: Enrolling
Updated:  12/26/2015
Children's Hospital Oakland
mi
from
Oakland, CA
ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
A 5 Year Observational Study (Registry) of Children Aged 2 to <6 Years at Enrollment With Transfusional Hemosiderosis Treated With Deferasirox
Status: Enrolling
Updated: 12/26/2015
Children's Hospital Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
A 5 Year Observational Study (Registry) of Children Aged 2 to <6 Years at Enrollment With Transfusional Hemosiderosis Treated With Deferasirox
Status: Enrolling
Updated:  12/26/2015
Children's Hospital of Orange County
mi
from
Orange, CA
ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
A 5 Year Observational Study (Registry) of Children Aged 2 to <6 Years at Enrollment With Transfusional Hemosiderosis Treated With Deferasirox
Status: Enrolling
Updated: 12/26/2015
Children's Hospital of Orange County
mi
from
Orange, CA
Click here to add this to my saved trials
ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
A 5 Year Observational Study (Registry) of Children Aged 2 to <6 Years at Enrollment With Transfusional Hemosiderosis Treated With Deferasirox
Status: Enrolling
Updated:  12/26/2015
Stanford Univ Med Ctr
mi
from
Stanford, CA
ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
A 5 Year Observational Study (Registry) of Children Aged 2 to <6 Years at Enrollment With Transfusional Hemosiderosis Treated With Deferasirox
Status: Enrolling
Updated: 12/26/2015
Stanford Univ Med Ctr
mi
from
Stanford, CA
Click here to add this to my saved trials
ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
A 5 Year Observational Study (Registry) of Children Aged 2 to <6 Years at Enrollment With Transfusional Hemosiderosis Treated With Deferasirox
Status: Enrolling
Updated:  12/26/2015
M.D. Anderson Cancer Center at Orlando
mi
from
Orlando, FL
ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
A 5 Year Observational Study (Registry) of Children Aged 2 to <6 Years at Enrollment With Transfusional Hemosiderosis Treated With Deferasirox
Status: Enrolling
Updated: 12/26/2015
M.D. Anderson Cancer Center at Orlando
mi
from
Orlando, FL
Click here to add this to my saved trials
ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
A 5 Year Observational Study (Registry) of Children Aged 2 to <6 Years at Enrollment With Transfusional Hemosiderosis Treated With Deferasirox
Status: Enrolling
Updated:  12/26/2015
St. Joseph's Children's Hospital of Tampa
mi
from
Tampa, FL
ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
A 5 Year Observational Study (Registry) of Children Aged 2 to <6 Years at Enrollment With Transfusional Hemosiderosis Treated With Deferasirox
Status: Enrolling
Updated: 12/26/2015
St. Joseph's Children's Hospital of Tampa
mi
from
Tampa, FL
Click here to add this to my saved trials
ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
A 5 Year Observational Study (Registry) of Children Aged 2 to <6 Years at Enrollment With Transfusional Hemosiderosis Treated With Deferasirox
Status: Enrolling
Updated:  12/26/2015
Children's Memorial Hospital
mi
from
Chicago, IL
ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
A 5 Year Observational Study (Registry) of Children Aged 2 to <6 Years at Enrollment With Transfusional Hemosiderosis Treated With Deferasirox
Status: Enrolling
Updated: 12/26/2015
Children's Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
A 5 Year Observational Study (Registry) of Children Aged 2 to <6 Years at Enrollment With Transfusional Hemosiderosis Treated With Deferasirox
Status: Enrolling
Updated:  12/26/2015
Children's Hospital Boston
mi
from
Boston, MA
ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
A 5 Year Observational Study (Registry) of Children Aged 2 to <6 Years at Enrollment With Transfusional Hemosiderosis Treated With Deferasirox
Status: Enrolling
Updated: 12/26/2015
Children's Hospital Boston
mi
from
Boston, MA
Click here to add this to my saved trials
ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
A 5 Year Observational Study (Registry) of Children Aged 2 to <6 Years at Enrollment With Transfusional Hemosiderosis Treated With Deferasirox
Status: Enrolling
Updated:  12/26/2015
Hackensack University Medical Center
mi
from
Hackensack, NJ
ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
A 5 Year Observational Study (Registry) of Children Aged 2 to <6 Years at Enrollment With Transfusional Hemosiderosis Treated With Deferasirox
Status: Enrolling
Updated: 12/26/2015
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
A 5 Year Observational Study (Registry) of Children Aged 2 to <6 Years at Enrollment With Transfusional Hemosiderosis Treated With Deferasirox
Status: Enrolling
Updated:  12/26/2015
St. Joseph's Children's Hospital
mi
from
Paterson, NJ
ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
A 5 Year Observational Study (Registry) of Children Aged 2 to <6 Years at Enrollment With Transfusional Hemosiderosis Treated With Deferasirox
Status: Enrolling
Updated: 12/26/2015
St. Joseph's Children's Hospital
mi
from
Paterson, NJ
Click here to add this to my saved trials
ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
A 5 Year Observational Study (Registry) of Children Aged 2 to <6 Years at Enrollment With Transfusional Hemosiderosis Treated With Deferasirox
Status: Enrolling
Updated:  12/26/2015
Brooklyn Hospital Center
mi
from
Brooklyn, NY
ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
A 5 Year Observational Study (Registry) of Children Aged 2 to <6 Years at Enrollment With Transfusional Hemosiderosis Treated With Deferasirox
Status: Enrolling
Updated: 12/26/2015
Brooklyn Hospital Center
mi
from
Brooklyn, NY
Click here to add this to my saved trials
ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
A 5 Year Observational Study (Registry) of Children Aged 2 to <6 Years at Enrollment With Transfusional Hemosiderosis Treated With Deferasirox
Status: Enrolling
Updated:  12/26/2015
Schneider Children's Hospital
mi
from
New York, NY
ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
A 5 Year Observational Study (Registry) of Children Aged 2 to <6 Years at Enrollment With Transfusional Hemosiderosis Treated With Deferasirox
Status: Enrolling
Updated: 12/26/2015
Schneider Children's Hospital
mi
from
New York, NY
Click here to add this to my saved trials
ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
A 5 Year Observational Study (Registry) of Children Aged 2 to <6 Years at Enrollment With Transfusional Hemosiderosis Treated With Deferasirox
Status: Enrolling
Updated:  12/26/2015
SUNY Upstate Medical University
mi
from
Syracuse, NY
ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
A 5 Year Observational Study (Registry) of Children Aged 2 to <6 Years at Enrollment With Transfusional Hemosiderosis Treated With Deferasirox
Status: Enrolling
Updated: 12/26/2015
SUNY Upstate Medical University
mi
from
Syracuse, NY
Click here to add this to my saved trials
ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
A 5 Year Observational Study (Registry) of Children Aged 2 to <6 Years at Enrollment With Transfusional Hemosiderosis Treated With Deferasirox
Status: Enrolling
Updated:  12/26/2015
East Carolina University
mi
from
Greenville, NC
ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
A 5 Year Observational Study (Registry) of Children Aged 2 to <6 Years at Enrollment With Transfusional Hemosiderosis Treated With Deferasirox
Status: Enrolling
Updated: 12/26/2015
East Carolina University
mi
from
Greenville, NC
Click here to add this to my saved trials
ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
A 5 Year Observational Study (Registry) of Children Aged 2 to <6 Years at Enrollment With Transfusional Hemosiderosis Treated With Deferasirox
Status: Enrolling
Updated:  12/26/2015
Akron Children's Hospital
mi
from
Akron, OH
ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
A 5 Year Observational Study (Registry) of Children Aged 2 to <6 Years at Enrollment With Transfusional Hemosiderosis Treated With Deferasirox
Status: Enrolling
Updated: 12/26/2015
Akron Children's Hospital
mi
from
Akron, OH
Click here to add this to my saved trials